Research programme: microbiome-based therapeutics - Hadasit/MyBiotics
Alternative Names: Microbiome based therapeutics - MyBiotics/HadasitLatest Information Update: 28 May 2025
At a glance
- Originator MyBiotics
- Class Antineoplastics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Skin cancer